GWPH News and Press, GW Pharmaceuticals Plc From 09/06/19

Cannabis advocates have long touted the medicinal benefits of cannabis, and more and more research is being conducted to test the plant’s potential to cure a number of ailments. Medical marijuana has been given to cancer patients for years to ease symptoms, but can cannabis cure ca...

CARLSBAD, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today annou...

In late August, Johnson & Johnson   (NYSE: JNJ) was hit with a hefty $572 million fine for its role in the opioid crisis in Oklahoma, which was still not as bad as it could have been . In what could prove to be a monumental case in the U.S., it could just be the beginning of a much...

GW Pharmaceuticals (NASDAQ: GWPH ) has had a very successful launch of "Epidiolex" in the USA. This, along with its promising pipeline, has been the main reason for the stock price gains it had enjoyed this year. However, recent news that the U.K. NHS (National Health Service) would not cu...

The World Health Organization made waves earlier this year by publishing its first marijuana review. The WHO had lots to say, including a call to place cannabis in a less restrictive schedule of the 1961 United Nations Single Convention on Narcotic Drugs. It might not seem like it, but bureaucr...

Over the long run, the marijuana industry is expected to show a lot of promise . Various Wall Street forecasts suggest that worldwide legal weed sales can grow from $10.9 billion in 2018 to anywhere between $50 billion and $200 billion in about a decade's time . That's growth that Wall Street ...

To a number of Wall Street pundits, the marijuana industry is the greatest thing since sliced bread . After delivering $10.9 billion in legal worldwide sales in 2018, the global pot industry could see sales soar to $200 billion in a decade . For those curious, that's a cool compound annual gro...

GWPH stock is one of the notable cannabis stock gainers in 2019. Let’s do a quick analysis of the recent developments from GW Pharmaceuticals (NASDAQ:GWPH). Epidiolex Holds Key As everyone knows, the ultimate aim of many marijuana companies is to get into the pharmaceutical secto...

About a month ago I wrote an article summarizing the investment opportunities and risks with Kalytera Therapeutics, Inc. ( KALTF ) (KLY.V). Since then, the company has released stunning Phase 2 clinical study data evaluating cannabidiol, or CBD, for the prevention of acute graft versus hos...

Some didn't think that  GW Pharmaceuticals   (NASDAQ: GWPH) would be able to successfully market the first FDA-approved drug made from the cannabis plant. They were wrong. Sales for GW's cannabidiol (CBD) drug Epidiolex have been fantastic. The tremendous launch of Epidiolex has enab...